| Tue, Feb 9, 2010 | | • | Marshall Edwards, Inc.'s Action Intended to Regain Compliance With Nasdaq Share Price Rule, Benefit Shareholders
Marketwire (Tue 3:30pm)
| | Mon, Feb 8, 2010 | | • | Marshall Edwards, Inc. Announces Resignation of Christopher Naughton From Board of Directors
Marketwire (Mon, Feb 8)
| | Thu, Jan 21, 2010 | | • | Analysis of Marshall Edwards, Inc.'s OVATURE Trial to Proceed Following Database Lock
Marketwire (Thu, Jan 21)
| | Mon, Dec 7, 2009 | | • | Culp, Novogen: Biggest Price Gainers (CFI, NVGN)
at The Wall Street Journal Online (Mon, Dec 7)
| | Tue, Dec 1, 2009 | | • | Marshall Edwards, Inc. Appoints Acting CEO
Marketwire (Tue, Dec 1)
| | Tue, Sep 29, 2009 | | • | Marshall Edwards, Inc.'s NV-128, a Novel mTOR Inhibitor, Demonstrates Good Safety Profile and High Anti-Cancer Activity In Vivo
Marketwire (Tue, Sep 29)
| | Tue, Sep 22, 2009 | | • | Marshall Edwards, Inc. Receives Nasdaq Notice of Minimum Bid Price Non-Compliance
Marketwire (Tue, Sep 22)
| | Tue, Aug 18, 2009 | | • | NOVOGEN LTD Financials
EDGAR Online Financials (Tue, Aug 18)
| | Wed, Aug 5, 2009 | | • | Marshall Edwards Licenses the Investigational Anti-Cancer Compound NV-128 From Novogen Limited
Marketwire (Wed, Aug 5)
| | Thu, Jul 30, 2009 | | • | Novogen Director Retires
Marketwire (Thu, Jul 30)
| | Tue, Jul 7, 2009 | | • | Researchers Discover That Phenoxodiol Kills Rapidly Proliferating T-Cells
Marketwire (Tue, Jul 7)
| | Wed, Jun 17, 2009 | | • | Independent Data Monitoring Committee Reviews Marshall Edwards, Inc.'s Arrangements for Data Analysis of the Ovature Trial
Marketwire (Wed, Jun 17)
| | Mon, Apr 20, 2009 | | • | Novogen's NV-128 Targets the mTOR Pathway to Block Differentiation and Induce Cell Death in Ovarian Cancer Stem Cells
Marketwire (Mon, Apr 20)
| | Tue, Apr 14, 2009 | | • | Marshall Edwards, Inc., to Undertake Analysis of Ovature Trial
Marketwire (Tue, Apr 14)
| | Mon, Mar 23, 2009 | | • | Board Changes at Novogen Limited Announced
Marketwire (Mon, Mar 23)
| | Thu, Mar 19, 2009 | | • | Biotech Analyst Joins Board of Directors of Marshall Edwards, Inc.
Marketwire (Thu, Mar 19)
| | Wed, Mar 18, 2009 | | • | Novogen's NV-128 Targets the mTOR Pathway to Induce Cell Death in Epithelial Ovarian Cancer Stem Cells
Marketwire (Wed, Mar 18)
| | • | Triphendiol Safety Data Clears the Way for Compound to Be Studied Further in the Treatment of Pancreatic Cancer
Marketwire (Wed, Mar 18)
| | Tue, Feb 24, 2009 | | • | Yale Researchers Present Results of Phase II Phenoxodiol Clinical Trial in Prostate Cancer Patients at ASCO 2009 Genitourinary Cancers Symposium
Marketwire (Tue, Feb 24)
| | Fri, Feb 13, 2009 | | • | Novogen to Focus on Oncology Program
Marketwire (Fri, Feb 13)
|
Add NVGN News to My Yahoo!:
 
| |
|
0.69% Nasdaq 
0.16 (6.84%) 
Headlines
